Bioinformatics Analysis of Hepatocellular Carcinoma Related Gene and Construction of a Protein-Protein Interaction Network

CAO Dan, YU Le, WANG Li-chun.

Abstract

To identify key genes associated with hepatocellular carcinoma (HCC) through analyzing the functions of differentially expressed genes (DEGs) and the interactions of their encoded proteins. Methods The microarray dataset GSE45436 was downloaded from the Gene Expression Omnibus (GEO) database. The DEGs in hepatocellular carcinoma and adjacent tissues were analyzed using the R software. Bioinformatics tools DAVIA, STRING, GEPIA, Cytoscape, cBioPortal were applied to analyze the biological functions of the DEGs and their encoded protein interactions. Results A total of 375 DEGs were identified, consisting of 296 downregulated genes and 99 upregulated genes. The enriched functions and pathways of the DEGs included cell cycle, p53 signaling pathway, complement activation, and metabolism of xenobiotics by cytochrome P450. The PPIanalysis showed that TOP2A might be involved in the carcinogenesis of HCC. Conclusions Differentially expressed genes in hepatocellular carcinoma and adjacent tissues and their encoded protein interactions revealed by the bioinformatics analysis provide guidance for further research on the molecular mechanism and targeted therapy of HCC. TOP2A may play a key role in HCC.

 

Keywords: Bioinformatics analysis, Hepatocellular carcinoma, Differentially expressed genes, Enriched functions and pathways 

 

Full Text:

PDF


References


EL-SERAG НИ, RUDOLPH KL. Hepatocellular carcinoma; epidemiology and molecular carcinogenesis. Gastroenterology,2007,132(7) :2557-2576.

HU Z, ZHOU Z, XIONG G, el al. Cyclin D1 G870A polymorphism and the risk of hepatocellular carcinoma in a Chinese population. Tumour Biol,2014 ,35(6);5607-5612.

BERASAINC, CASTILLO J, PRIETO J, et at. New molecular targets for hepatocellular carcinoma; the ErbBl signaling system. Liver Int,2007,27(2); 174-185.

GAN FY. GESELL MS, ALOUSI M, et al. Analysis of ОГХ and c-myc gene expression in hepatocellular carcinoma by in situ hybridization and immunohistochemistry. J Histochem Cytochem, 1993,41(8); 1185-1196.

NEWELL P, TOFFANIN S, VILLANUEVA A, et al. Ras pathway activation in hepatocellular carcinoma and anti- tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol,2009,51(4) :725-733.

KIM I, XU W, REED JC. Cell death and endoplasmic reticulum stress; disease relevance and therapeutic opportunities. Nat Rev Drug Discov,2008,7( 12): 1013-1030.

WATANUKI A, OHWADA S, FUKUSATO T, et al. Prognostic significance of DNA topoisomerase li alpha expression in human hepatocellular carcinoma. Anticancer Res,2002,22( 2B): 1113-1119.

WONG N, YEO W. WONG WL, et al. TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance. Int J Cancer,2009,124(3);644-652.

LI J, GAO JZ, DU JL, et al. Increased CDC20 expression is associated with development and progression of hepatocellular carcinoma. Int J Oncol,2014,45(4): 1547-1555.

CAO L, LI C, SHEN S, et al. OCT4 increases BIRC5 and CCND1 expression and promotes cancer progression in hepatocellular carcinoma. BMC Cancer, 2013, 13 ( 1); 82 [ 2013-02-22 ]. littps; //www. ncbi. nlm. nib. gov/pmc/ articles/PMC3583731/pdf/1471-2407-13-82. pdf. doi; 10. 1186/1471-2407-13-82.

ZHANG Y, HUANG W, RAN Y, et al. miR-582-5p inhibits proliferation of hepatocellular carcinoma by targeting CDK1 and AKT3. Tumour Biol,2015 ,36( 11) ;8309-8316.

MENGX, FRANKLIN DA, DONG J, et al. MDM2-p53 pathway in hepatocellular carcinoma. Cancer Res, 2014, 74 (24):7161-7167.

MOLINA-ORTIZ D, CAMACHO-CARRANZA R, GONZ LEZ-ZAMORA JF, et al. Differential expression of cytochrome P450 enzymes in normal and tumor tissues from childhood rhabdomyosarcoma. PLoS One,2014 ,9(4) ;e93261 [2014-04-03]. https$//dx. doi. org/10. 1371/journal, pone. 0093261.


Refbacks

  • There are currently no refbacks.